Related Experiment Videos
Mifepristone-induced vaginal bleeding is associated with increased immunostaining for cyclooxygenase-2 and decrease
Dharani K Hapangama1, Hilary O D Critchley, Teresa A Henderson
1Contraceptive Development Network, Centre for Reproductive Biology, University of Edinburgh, 37 Chalmers Street, Edinburgh EH3 9ET, Scotland, UK. cdn@ed.ac.uk
The Journal of Clinical Endocrinology and Metabolism
|November 5, 2002
Summary
Mifepristone causes vaginal bleeding by increasing local prostaglandins in the endometrium. This occurs as progesterone levels drop and key enzymes like cyclooxygenase-2 increase, while prostaglandin 15 dehydrogenase decreases.
Area of Science:
- Reproductive Endocrinology
- Pharmacology
Background:
- Mifepristone is used clinically, but its mechanism for inducing endometrial shedding and bleeding in the luteal phase requires further elucidation.
- Understanding the molecular pathways involved is crucial for optimizing its therapeutic applications.
Purpose of the Study:
- To investigate the biochemical mechanisms underlying mifepristone-induced vaginal bleeding and endometrial shedding during the midluteal phase.
- To examine the role of prostaglandins and their metabolizing enzymes in this process.
Main Methods:
- A study involving 13 women administered mifepristone during the midluteal phase (LH+8).
- Endometrial biopsies were collected at 6-24 hours and 36-48 hours post-mifepristone.
- Immunohistochemical analysis of cyclooxygenase-2 (COX-2), prostaglandin 15 dehydrogenase (PG15DH), and steroid receptors was performed and compared to controls.
Main Results:
- All participants experienced vaginal bleeding 36-48 hours after mifepristone administration.
- Mifepristone significantly reduced serum progesterone levels compared to controls.
- Increased cyclooxygenase-2 immunoreactivity and decreased prostaglandin 15 dehydrogenase expression were observed in the endometrium by 36-48 hours post-treatment.
Conclusions:
- The observed changes in COX-2 and PG15DH strongly support the hypothesis that increased local prostaglandin concentration mediates mifepristone-induced luteal phase bleeding.
- These findings highlight the critical role of prostaglandin metabolism in the endometrial response to mifepristone.